Key result
CRT-D is being evaluated to determine if it reduces mortality and heart failure events by 25% in patients with NYHA class I-II cardiomyopathy, EF ≤0.30, and QRS ≥130 ms.
Why the study?
Does CRT-D reduce the risk of mortality and HF events in subjects with ischemic (NYHA class I-II) and non-ischemic (NYHA class II) cardiomyopathy, left ventricular dysfunction (EF ≤0.30), and prolonged intraventricular conduction (QRS duration ≥130 ms)?
Population
Subjects with ischemic and non-ischemic cardiomyopathy, left ventricular dysfunction, and prolonged…
Design
Other
Authors
Loading...
This paper outlines the design and protocol for the MADIT-CRT trial evaluating CRT-D in patients with mild heart failure, reduced ejection fraction, and prolonged QRS duration.
Does CRT-D reduce the risk of mortality and HF events in subjects with ischemic (NYHA class I-II) and non-ischemic (NYHA class II) cardiomyopathy, left ventricular dysfunction (EF ≤0.30), and prolonged intraventricular conduction (QRS duration ≥130 ms)?
This paper outlines the design and protocol for the MADIT-CRT trial evaluating CRT-D in patients with mild heart failure, reduced ejection fraction, and prolonged QRS duration.
Moss et al. (2005) studied this question. CRT-D is being evaluated to determine if it reduces mortality and heart failure events by 25% in patients with NYHA class I-II cardiomyopathy, EF ≤0.30, and QRS ≥130 ms.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: